Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

18.03
-0.1700-0.93%
Pre-market: 18.640.6100+3.38%04:18 EDT
Volume:1.79M
Turnover:32.42M
Market Cap:2.26B
PE:-11.29
High:18.72
Open:18.00
Low:17.68
Close:18.20
Loading ...

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Benzinga
·
06 Mar

UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating

MT Newswires Live
·
05 Mar

Stock Track | Apellis Pharmaceuticals Soars 5.07% as JP Morgan Maintains Overweight Rating

Stock Track
·
05 Mar

Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

Zacks
·
03 Mar

Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush

Dow Jones
·
03 Mar

Apellis Pharmaceuticals Inc : Wedbush Cuts Target Price to $29 From $30

THOMSON REUTERS
·
03 Mar

Apellis Pharmaceuticals (APLS) Receives a Hold from Scotiabank

TIPRANKS
·
03 Mar

Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

RBC Trims Price Target on Apellis Pharmaceuticals to $25 From $26, Keeps Sector Perform Rating

MT Newswires Live
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), DENTSPLY SIRONA (XRAY) and Cytokinetics (CYTK)

TIPRANKS
·
03 Mar

Apellis price target lowered to $44 from $47 at BofA

TIPRANKS
·
03 Mar

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
01 Mar

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

GuruFocus.com
·
01 Mar

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts

TIPRANKS
·
01 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines

Reuters
·
28 Feb

Stock Track | Apellis Pharmaceuticals Plummets 5.31% Despite Better-Than-Expected Q4 Earnings

Stock Track
·
28 Feb

Apellis Pharmaceuticals Shares Reverse Course From Premarket Gains; Last Down 4.4%

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb